• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Ditropan XL (oxybutynin, USP) Extended Release tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2009

 

Summary View

 

ADVERSE REACTIONS

Postmarketing Surveillance
  • memory impairment
  • Cardiac Disorders: QT interval prolongation